Regulated information

Bilan semestriel des moyens alloués au contrat de liquidité (2009) - french

Au 30 juin 2009

Bilan semestriel des moyens alloués au contrat de liquidité (2009) - french

Au 31 décembre 2009

Bilan semestriel des moyens alloués au contrat de liquidité (2008) - french

Au 30 juin 2008

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 30 juin 2019

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2019

Bilan semestriel des moyens alloués au contrat de liquidité (2012) - french

Au 30 juin 2012

Bilan semestriel des moyens alloués au contrat de liquidité (2012) - french

Au 31 décembre 2012

Bilan semestriel des moyens alloués au contrat de liquidité (2013) - french

Au 30 juin 2013

Bilan semestriel des moyens alloués au contrat de liquidité (2007) - french

Au 30 juin 2007

Bilan semestriel des moyens alloués au contrat de liquidité (2008) - french

Au 31 décembre 2008

Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french

Au 31 décembre 2016

Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french

Au 31 décembre 2016

Bilan semestriel des moyens alloués au contrat de liquidité (2017) - french

Au 30 juin 2017

Bilan semestriel des moyens alloués au contrat de liquidité (2015) - french

Au 31 décembre 2015

Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french

Au 31 décembre 2016

Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french

Au 30 juin 2016

Bilan semestriel des moyens alloués au contrat de liquidité (2013) - french

Au 31 décembre 2013

Bilan semestriel des moyens alloués au contrat de liquidité (2014) - french

Au 30 juin 2014

Bilan semestriel des moyens alloués au contrat de liquidité (2014) - french

Au 31 décembre 2014

Bilan semestriel des moyens alloués au contrat de liquidité (2015) - french

Au 30 juin 2015

Bilan semestriel des moyens alloués au contrat de liquidité (2011) - french

Au 31 décembre 2011

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 30 juin 2020

Bilan semestriel des moyens alloués au contrat de liquidité (2010) - french

Au 30 juin 2010 :

Bilan semestriel des moyens alloués au contrat de liquidité (2010) - french

Au 31 décembre 2010

Bilan annuel des moyens alloués au contrat de liquidité (décembre 2021)

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2021

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020

Buyback programs - April 2024

Monthly communication regarding buyback programs

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

Vétoquinol enters the indian market

June 29, 2009 (Lure, France) – Vétoquinol today announced the signing of an agreement for the acquisition of the Animal Health Division of Wockhardt Limited, based in Mumbaï, India.

Growth in Revenues in the first half of 2009

Vétoquinol’s revenues in the first half of 2009 totalled EUR 119.9 million, an increase of 2.7% compared to the first half of the preceding year.

Vétoquinol completes the acquisition of Wockhardt Animal Health in India

August 20, 2009 (Lure, France) – Vétoquinol today announced the completion of its acquisition of the animal health business division of Wockhardt Limited, based in Mumbaï, India. This acquisition was the subject of an agreement signed with the Wockhardt Limited group on June 26.

Vétoquinol posts resilient results in the first half of 2009 and continues to pursue its international growth

The Board of Directors of Vétoquinol, meeting on August 27, reviewed the group’s business and approved the group’s interim 2009 financial statements.

Strong growth in Revenues in the 3rd quarter

Vétoquinol recorded strong growth in the 3rd quarter of 2009, despite an unfavourable exchange rate effect. The strength in sales was due to a combination of the contribution of acquisitions in Italy and India and sustained organic growth.

Matthieu Frechin named Managing Director of Vétoquinol

December 14, 2009 (Lure, France) – The Board of Directors of Vétoquinol, at its December 10
meeting, has named Matthieu Frechin Managing Director of the Vétoquinol Group, replacing
Etienne Frechin. He will be seconded by Dominique Henryon, Deputy General Manager.
Etienne Frechin will give up all operating functions but will continue to serve as Chairman of
Vétoquinol’s Board of Directors.

VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States

January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

Redemption of tranche A bonds

February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds.

2009 annual earnings

March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements.

Departure of Pierre Konareff

April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre
Konareff, Group Director of Finance and Legal Affairs, because of differences concerning his
position in the Group. Pierre Konareff joined Vétoquinol in July 2008.

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2009 (french version)

The registration document of Vétoquinol relative to fiscal year 2009, including the annual financial report relative to fiscal year 2009, was registered with the Autorité des marchés financiers (“the AMF”) on April 22th, 2010.

BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle

June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle.

Sustained revenue growth in 2006

KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french)

Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées

Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées.

First nine months 2022 sales: €405M

In line with year-end outlook

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

Combined ordinary and extraordinary general meeting May 21, 2019

The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin.

Vetoquinol announces a new milestone in its industrial strategy

Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners.

First half 2019 results

At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.

Q3 2019 sales: €100.2 million (Up 11.0%)

The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year.

Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement

December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China.

2019 sales: €396.0 million (Up 7.6%)

The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.

Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK

February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health.

Covid-19: Vetoquinol donates masks to neighboring healthcare facilities

Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions.

2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales)

At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Q1 2020 sales €103.4 million (Up 13.7%)

Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates.

Availability of the 2019 universal registration document

Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020.

Dominique Derveaux appointed Group Chief Operations Officer Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin.

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

Flevox® the new parasiticide for dogs and cats

Lure (France), 14 February 2012 – Vétoquinol launches Flevox®, the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets.

2011 annual earnings

Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements.

Strong Revenue growth in the first quarter of 2012

Vétoquinol achieved Q1 2012 sales of €77.0 million, up 15.9% compared to Q1 2011.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2011 (french version)

The registration document of Vétoquinol relative to fiscal year 2011, including the annual financial report relative to fiscal year 2011, was registered with the Autorité des marchés financiers (“the AMF”) on April 20th, 2012.

Solid first half 2012 Sales

First half 2012 sales reached €146.8 million, up 5.1% over first half 2011.

Vétoquinol returns to growth

Lure (France), 29 August 2012 – At its 29 August 2012 meeting, the Vétoquinol S.A. board of directors reviewed the Group results and approved the financial statements for the first six months of 2012.

Vétoquinol purchases ORSCO laboratoire vétérinaire

Lure (France), September 25, 2012 – Vétoquinol announces the purchase of the entire equity of Orsco Laboratoire Vétérinaire.

Sales momentum continues in Q3

Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year.

Forcyl® - a booming brand

Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs.

2012 sales up 5.0%

Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%.

2012, return to growth

Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements.

Q1 2013 sales

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2012 (french version)

The registration document of Vétoquinol relative to fiscal year 2012, including the annual financial report relative to fiscal year 2012, was registered with the Autorité des marchés financiers (“the AMF”) on April 15th, 2013.

Q2 2013 sales

Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like.

The reference products demonstrate solid growth

Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013.

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

Vétoquinol strengthens its position in the United States

Vétoquinol reports one of its industry’ strongest growth performances in 2006

Annual earnings for 2006: a year of good performance

Présentation des résultats 2006 de Vétoquinol (french)

2006 Financial Report

Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent.
Le résultat opérationnel courant, qui s’élève à 25,6 M€, est en augmentation de 10,8%.
Enfin, le résultat net de 15,8 M€ progresse de 27,2% et représente 7,5% du chiffre d’affaires.
Cette croissance a été maîtrisée et équilibrée.

Activity Report 2006

Vétoquinol creates a subsidiary in Portugal

Business is strong in first-half of 2007 : + 12.9%

2007 Half year Financial Report

Rapport semestriel 2007 « narratif » (french)

Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un
chiffre d’affaires de 111,1 M€ contre 98,4 M€ au cours de la même période de l’exercice
précédent, soit une progression de 12,9 %.
A cours de change et périmètre constants, la progression est de 10,1 %.

Reports very good first half, confirming that 2007 performance is set to surpass targets

Presentation of Vétoquinol’s results for the first half of 2007

2007 Half year results

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

Vétoquinol to market and distribute Vetprofen in the United States

Vétoquinol announces opening of its first decentralized R&D center in Canada

Revenue grows by 10.3% in 2007, to €233.4 M

VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe

Earnings for 2007 attest to strength of business growth model

The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance
indicators, ahead of its medium-term targets. According to the most recent statistics published by Vetnosis, this substantial rise in revenue has lifted Vétoquinol to third place
worldwide.

Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis

Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment.

Vétoquinol strengthens its presence in Canada in the compagnion animal market

Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC. The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada.